John J. Crowley
Ph.D., University of Washington, 1973.
Design And Analysis Of Cancer Clinical Trials.
The Southwest Oncology Group (SWOG) is a national consortium of institutions and investigators whose mission is to make progress in the prevention and cure of cancer through clinical research. The Statistical Center, located in the Division of Public Health Sciences of the FHCRC, contributes to this mission through study design, protocol development, data management and quality control, data analysis, and statistical research.
SWOG has over 100 trialsopen for patient accrual in all sites of cancer, plus a large prostate cancer prevention trial. Recent advances have been made in the treatment of ovarian, bladder, prostate, lung, colon, and head and neck cancers. The Statistical Center's efforts are carried out by a staff of over 65 people, including eight faculty biostatisticians and a behavioral scientist.
My own emphasis within SWOG is in lung cancer and multiple myeloma. In addition to the design and analysis of trials in these disease sites,including a randomized study of high dose therapy and autologous transplantation in myeloma, I have been involved in assessing the importance of various laboratory findings in predicting survival and forming prognostic groups. My longstanding interest in developing exploratory tools for survival data has found fruitful application in these areas. My other current interest is in the education of cancer clinicians in the principles and pitfalls of cancer clinical trials.
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.. Clinical trials (London, England).. 2013.
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.. Haematologica. 98(7):1147-53.. 2013.
The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 8(12):1467-73.. 2013.
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 306(14):1549-56.. 2011.
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.. American journal of hematology. 86(1):25-30.. 2011.
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(4):640-6.. 2011.
Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.. Clinical lymphoma, myeloma & leukemia. 11(1):139-42.. 2011.
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4747-54.. 2010.
Should the 7th edition of the lung cancer stage classification system change treatment algorithms in non-small cell lung cancer? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 5(11):1779-83.. 2010.
Survival and years of life lost in different age cohorts of patients with multiple myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(9):1599-605.. 2010.
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9.. 2010.
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(7):1209-14.. 2010.
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3023-7.. 2010.
[The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer].. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 13(1):9-18.. 2010.